

# ClariVein<sup>®</sup> OC



- Non-tumescent
- Non-thermal
- Clinically Proven
- Reduced Pain\*
- Reduced Recovery Time<sup>1</sup>
- Fast Procedure Time\*

**The ClariVein<sup>®</sup> OC** is a specialty infusion catheter with a rotating wire tip designed for the controlled 360-degree dispersion of physician-specified agents to the targeted treatment area

\* R. van Eekeren, et al. Postoperative Pain and Early Quality of Life After Radiofrequency Ablation and Mechanochemical Endovenous Ablation of Incompetent Great Saphenous Veins, Journal of Vascular Surgery, Volume 57 Number 2, February 2013, p. 445-450.



# VeinCLEAR™ An Advanced Endovenous Thermal Ablation System



## RF Generator V-700

Features Specialized Modes for Varicose Vein Treatment



## VeinCLEAR™ Catheters


Expertly Designed for Endovenous Thermal Ablation




### + Available Options



### + Markings for Segmental Ablation



### + Heating Element Length



# Medtronic solutions for lower extremity varices



## ClosureFast™

The ClosureFast™ Procedure, with its patented overlap design, is the only RFA procedure with published long-term clinical data demonstrating safety and efficacy, with a 91.9% closure rate at 5 years.<sup>1-2</sup>

## VenaSeal™

Reach new lengths and treat more diseased vein with the VenaSeal™ Closure System. The VenaSeal™ Closure System delivers immediate and lasting vein closure with its proprietary medical adhesive formula, with a demonstrated 94.6% closure rate at 5 years.<sup>3-7</sup>



1. Proebstle TM, Alm BJ, Göckeritz O, et al. Five-year results from the prospective European multicentre cohort study on radiofrequency segmental thermal ablation for incompetent great saphenous veins. *Br J Surg*. February 2015;102(3):212-216.  
2. ClosureFast and ClosureFast RFS Patents. Available at [www.medtronic.com/patents](http://www.medtronic.com/patents). Accessed March 9, 2021.  
3. Morrison N, Gibson K, McEnroe S, et al. Randomized trial comparing cyanoacrylate embolization and radiofrequency ablation for incompetent great saphenous veins (VeClose). *J Vasc Surg*. April 2015;61(4):985-994.  
4. Proebstle T, Alm J, Dimitri S, et al. Three-year follow-up results of the prospective European Multicenter Cohort Study on Cyanoacrylate Embolization for treatment of refluxing great saphenous veins. *J Vasc Surg Venous Lymphat Disord*. March 2021;9(2):329-334.  
5. Gibson K, Ferris B. Cyanoacrylate closure of incompetent great, small and accessory saphenous veins without the use of post-procedure compression: Initial outcomes of a post-market evaluation of the VenaSeal System (the WAVES Study). *Vascular*. April 2017;25(2):149-156.  
6. Almeida JL, Javier JJ, Mackay EG, Bautista C, Cher DJ, Proebstle TM. Thirty-six month follow-up of first-in-human use of cyanoacrylate adhesive for treatment of saphenous vein incompetence. *J Vasc Surg Venous Lymphat Disord*. September 2017;5(5):658-666.  
7. Morrison N, Gibson K, Vasquez M, Weiss R, Jones A. Five-year extension study of patients from a randomized clinical trial (VeClose) comparing cyanoacrylate closure versus radiofrequency ablation for the treatment of incompetent great saphenous veins. *J Vasc Surg Venous Lymphat Disord*. November 2020;8(6):978-989.